CTLA4 as Immunological Checkpoint in the Development of Multiple Sclerosis.
about
Neuro-ophthalmic side effects of molecularly targeted cancer drugs.Inflammatory CNS disease caused by immune checkpoint inhibitors: status and perspectives.Nature, nurture, and microbes: The development of multiple sclerosis.Motor polyradiculopathy during pembrolizumab treatment of metastatic melanoma.Seronegative antibody-mediated neurology after immune checkpoint inhibitors.Tissue-resident memory T cells populate the human brainNeurological complications of immune checkpoint inhibitors: what happens when you 'take the brakes off' the immune system
P2860
Q47625145-0A13017C-48F2-4B68-8C71-6D58E159647FQ47986213-728137CB-45FE-4053-9C67-DAC5D14CBFB9Q48001628-9A97CDBD-1C3E-42E5-B011-164B977CA5C8Q48236699-8E634B43-D655-4A7B-87E0-3FC9A8D8E828Q55022473-560C1DB5-AA98-4CF1-9C5B-F332102B91EAQ58617537-E062C9BE-3B80-4BF0-88A1-76737A84C471Q58740161-13FB503A-CB14-49AA-BC10-B9926A0117BD
P2860
CTLA4 as Immunological Checkpoint in the Development of Multiple Sclerosis.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
CTLA4 as Immunological Checkpoint in the Development of Multiple Sclerosis.
@en
CTLA4 as Immunological Checkpoint in the Development of Multiple Sclerosis.
@nl
type
label
CTLA4 as Immunological Checkpoint in the Development of Multiple Sclerosis.
@en
CTLA4 as Immunological Checkpoint in the Development of Multiple Sclerosis.
@nl
prefLabel
CTLA4 as Immunological Checkpoint in the Development of Multiple Sclerosis.
@en
CTLA4 as Immunological Checkpoint in the Development of Multiple Sclerosis.
@nl
P2093
P2860
P356
P1433
P1476
CTLA4 as Immunological Checkpoint in the Development of Multiple Sclerosis.
@en
P2093
Andreas Junker
Andreas Straube
Birgit Ertl-Wagner
Carola Berking
Eduardo Beltrán
Julia K Tietze
Jörg C Prinz
Kathrin Held
Klaus Dornmair
Reinhard Hohlfeld
P2860
P304
P356
10.1002/ANA.24715
P577
2016-06-28T00:00:00Z